The new therapy proposed is based on a peptide analog of Cortistatin, efficacious as anti-inflammatory and modulator of the immune response and with an improved systemic half-life with respect tto the endogenous peptide.

Its therapeutic effect was tested in several preclinical models of inflammatory bowel disease and it was even more effective than current reference treatments used clinically for these patients, such as infliximab and mesalazine.

This work has been the result of a multidisciplinar collaboration between BCN Peptides and researchers from the Institut of Recerca Biomèdica – Barcelona and the Instituto de Parasitologíay Biomedicina López Neyra – CSIC Granada (IPBLN-CSIC).

The results have been published in Nature Communications.

https://www.nature.com/articles/s41467-021-22076-5

The new therapy proposed is based on a peptide analog of Cortistatin, efficacious as anti-inflammatory and modulator of the immune response and with an improved systemic half-life with respect to the endogenous peptide. Its therapeutic effect was tested in several preclinical models of inflammatory bowel disease and it was even more effective than current reference treatments used clinically for these patients, such as infliximab and mesalazine.

This work has been the result of a multidisciplinar collaboration between BCN Peptides and researchers from the Institut of Recerca Biomèdica – Barcelona and the Instituto de Parasitología y Biomedicina López Neyra – CSIC-Granada (IPBLN-CSIC).

The results have been published in Nature Communicacions.

https://doi.org/10.1038/s41467-021-22076-5

BCN Peptides has been a key GAPVAC European Consortium member that has performed the first-in-human Clinical trial of a Personalized Therapeutic Vaccine to treat Glioblastoma. BCN Peptides role was the Manufacture of the GMP Peptide Library used for the Vaccine production. We are proud to announce that the demonstration of the proof-of-concept for the Personalized approach has been published by Nature on date 19th December, 2018 (https://www.nature.com/articles/s41586-018-0810-y/newly diagnosed glioblastoma | Nature ). For more information you can download the GAPVAC Press release. BCN Peptides is completely committed with the growth of Personalized Medicine, as we consider this is a strategic therapy for the treatment of oncology patients in the neaw future. For this reason we are actively developing solutions for the challenges that Individualized Drug production represents for the Pharma Industry. (http://gapvac.eu/nature-publication-reports-first-in-human-trial-of-a-novel-actively-personalized-therapeutic-vaccine-for-brain-cancer/)